Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.45 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6011462 | 0.83 | FOLH1 (0.50) | GLAFOLH1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2154019 | 0.82 | GLA (0.53) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL2153847 | 0.82 | HRH3 (0.59) | GLAFOLH1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5090668 | 0.80 | GLA (0.51) | GLAFOLH1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL25588020 | 0.79 | KDM1A (0.51) | GLAFOLH1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3063453 | 0.78 | ENPP2 (0.53) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL580840 | 0.78 | LOXL2 (0.61) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL126484 | 0.78 | GLA (0.50) | GLAFOLH1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL92972 | 0.78 | GLA (0.50) | GLAFOLH1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL12652976 | 0.78 | GLA (0.50) | GLAFOLH1CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111763164-B | Preparation method and application of ortho-carbonyl amino substituted benzene derivatives | 中国医学科学院药物研究所 | 2023-03-10 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-111763164-A | Preparation method and application of ortho-carbonyl amino substituted benzene derivatives | 中国医学科学院药物研究所 | 2020-10-13 | — | — | CN | disclosed |
| CN-111517902-A | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2019057723-A1 | HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-03-28 | — | — | WO | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| WO-2003053437-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GLA 970/4885FOLH1 2838/4885CYP19A1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.